|
⚲
|
| Keyboard |
| OrbiMed Advisors LLC
✚
|
|
|---|---|
| CRD # | 118608 |
| SEC # | 801-61046 |
| CIK # | 0001491569, 0001055951 |
| AUM | 20.61 B (2026-03-25) |
| Employees | 118 (73% Investors, 0% Brokers) |
| Phone | 212-739-6400 |
| Address | 601 Lexington Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] [Facebook] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Edgewise Therapeutics Inc | 0.5 | ||
| Imara Inc | 0.3 | ||
| Avita Medical Ltd | 0.3 | ||
| Mdxhealth Sa | 0.3 | ||
| Lilly Eli & Co | 0.2 | ||
| Boston Scientific Corp | 0.1 | ||
| Sionna Therapeutics Inc | 0.1 | ||
| Astrazeneca PLC | 0.1 | ||
| Myriad Genetics Inc | 0.1 | ||
| MBX Biosciences Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | OrbiMed Royalty & Credit Opportunities V Offshore LP | [2026-03-25] | 1,243.5 M | 788.6 M |
| Offered $1,750,000,000 · Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $506,475,000 · Duration One year or less · Revenue Not Applicable | ||||
| Other | OrbiMed Private Investments X LP | [2026-02-25] | 1,572.9 M | |
| Offered $1,750,000,000 · Filed 2025-09-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,750,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| PE | OrbiMed Royalty & Credit Opportunities V LP | [2026-02-25] | 1,243.5 M | 1,128.1 M |
| Offered $1,750,000,000 · Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $506,475,000 · Duration One year or less · Revenue Not Applicable | ||||
| PE | OrbiMed Royalty & Credit Opportunities IV Offshore LP | [2023-02-28] | 344.5 M | 567.9 M |
| Offered $500,000,000 · Filed 2022-12-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $155,549,600 · Duration One year or less · Revenue Not Applicable | ||||
| HF | OrbiMed Partners SPV Ltd | 2022-11-14 | 102.5 M | |
| Other | OrbiMed Asia Partners V LP | [2022-08-03] | 651.9 M | 947.9 M |
| Offered $1,100,000,000 · Filed 2022-11-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $448,127,986 · Duration One year or less · Revenue Not Applicable | ||||
| Other | OrbiMed Private Investments IX LP | [2022-08-03] | 1,849.5 M | 2,190.7 M |
| Offered $1,900,000,000 · Filed 2023-04-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $50,450,000 · Duration More than one year · Revenue Not Applicable | ||||
| PE | OrbiMed Royalty & Credit Opportunities IV LP | [2022-08-03] | 1,153.1 M | 1,417.7 M |
| Offered $1,750,000,000 · Filed 2022-12-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $596,875,400 · Duration One year or less · Revenue Not Applicable | ||||
| Other | OrbiMed Private Investments VIII LP | [2020-11-25] | 1,683.2 M | |
| Offered $1,400,000,000 · Filed 2020-08-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,400,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | OrbiMed New Horizons Master Fund LP | [2020-08-21] | 86.7 M | 13.6 M |
| Filed 2023-04-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 32 | 20.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 32 | 20.6 |
| By Discretionary | ||
| Discretionary | 32 | 20.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 32 | 20.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 10.2 | |
| United States Persons | 10.4 | |
| Total | 32 | 20.6 |
| Limited Partners | 2011 - 2026 |
|---|---|
| California State Teachers' Retirement System | |
| Oregon Public Employees Retirement Fund |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Brian Burkholder | Director | 71 | 22 | |
| John Collis | Director | 97 | 14 | |
| David Wang | Director | 40 | 7 | |
| Jonathan Wang | Director | 42 | 4 | |
| Samuel Isaly | Director, Executive Officer, Promoter | 21 | 3 | |
| Carl Gordon | Director, Executive Officer | 112 | 2 | |
| Peter Thompson | Executive Officer | 61 | 2 | |
| Jonathan Silverstein | Director, Executive Officer | 57 | 2 | |
| David Bonita | Executive Officer | 55 | 2 | |
| Sven Borho | Director, Executive Officer | 27 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001055951] | |
| 3 | [0001055951] | |
| 4 | [0001055951] | |
| SC 13D | [0001055951] | |
| SC 13G | [0001055951] | |
| 3 | [0001491569] | |
| 4 | [0001491569] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $6.7B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 57G4FX4JA0RP0CHYJ782 |
| Related People Network |
|---|
| 43 people file Form D offerings alongside this firm's people. |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Sionna Therapeutics Inc SION
Common Stock
|
2026-02-03 | Sell | 29,063 | $44.58 | 1,295,629 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2026-02-02 | Sell | 1,890 | $44.57 | 84,237 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-12-24 | Sell | 33,356 | $44.55 | 1,486,010 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-12-19 | Sell | 875 | $44.49 | 38,929 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-12-18 | Sell | 100 | $44.49 | 4,449 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-12-17 | Sell | 900 | $44.50 | 40,050 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-11-26 | Sell | 1,600 | $44.49 | 71,184 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-11-25 | Sell | 11,890 | $44.60 | 530,294 |
|
Sionna Therapeutics Inc SION
Common Stock
|
2025-11-24 | Sell | 94,583 | $44.54 | 4,212,727 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 74,465 | $17.75 | 1,321,754 |
|
Keros Therapeutics Inc KROS
Common Stock
|
2025-11-21 | Disposed to issuer | 140,057 | $17.75 | 2,486,012 |
|
PMV Pharmaceuticals Inc PMVP
Common Stock
|
2025-10-23 | Sell | 1,000,000 | $1.52 | 1,520,000 |
|
Adicet Bio Inc ACET
Common Stock
|
2025-10-08 | Buy | 3,500,000 | $1.00 | 3,500,000 |
|
Adicet Bio Inc ACET
Common Stock
|
2025-10-08 | Buy | 1,500,000 | $1.00 | 1,500,000 |
|
Turnstone Biologics Corp TSBX
Common Stock
|
2025-08-08 | Tender | 3,099,265 | ||
|
ImageneBio Inc IKNA
Common Stock
|
2025-07-25 | Grant | 83,611 | $2.49 | 208,191 |
|
Corvus Pharmaceuticals Inc CRVS
Common Warrants (right to buy) · derivative
|
2025-06-27 | Option exercise | 1,397,684 | $0.00 | |
|
Corvus Pharmaceuticals Inc CRVS
Common Stock
|
2025-06-27 | Option exercise | 1,397,684 | $3.50 | 4,891,894 |
|
Corvus Pharmaceuticals Inc CRVS
Common Stock
|
2025-06-27 | Sell | 1,176,332 | $4.16 | 4,893,541 |
|
Passage Bio Inc PASG
Common Stock
|
2025-06-26 | Sell | 213,257 | $0.33 | 70,375 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Benefit Street Partners Limited
✚
|
22.61 B | |
|
Crestline Management LP
✚
|
TX | 22.51 B |
|
Dawson Partners Inc
✚
|
22.14 B | |
|
Lone Pine Capital LLC
✚
|
CT | 21.62 B |
|
Hildene Capital Management LLC
✚
|
CT | 20.18 B |
|
Deerfield Management Company LP
✚
|
NY | 19.08 B |
|
Blackstone Liquid Credit Strategies LLC
✚
|
NY | 18.79 B |
|
Altimeter Capital Management LP
✚
|
CA | 18.75 B |
|
Fundsmith LLP
✚
|
18.51 B | |
|
Rock Creek Group LLC
✚
|
DC | 18.38 B |